Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3797-3805

  Lust, Sofie ^a   Vanhoecke, Barbara ^a   Van Gele, Mireille ^a   Boelens, Jerina ^a   Van Melckebeke, Heleen ^a   Kaileh, Mary ^b   Vanden Berghe, Wim ^b   Haegeman, Guy ^b   Philippé, Jan ^a   Bracke, Marc ^a   Offner, Fritz ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; ER stress; Proteasome; XBP1 splicing

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; CASPASE 3; CASPASE 4; CASPASE 9; CCAAT ENHANCER BINDING PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEIN BCL 2; PROTEIN KINASE R; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; RITUXIMAB; X BOX BINDING PROTEIN 1; XANTHOHUMOL;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SEQUENCE HOMOLOGY; UPREGULATION; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 6; AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASES; CYSTEINE PROTEINASE INHIBITORS; EIF-2 KINASE; ENDORIBONUCLEASES; FLAVONOIDS; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; NF-KAPPA B; PROPIOPHENONES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; UNFOLDED PROTEIN RESPONSE;

EID: 71949101502     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Montserrat E and Rozman C: Chronic lymphocytic leukemia: present status. Ann Oncol 6: 219-235, 1995.
2. Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ and Huang P: Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia 18: 1934-1940, 2004.
3. Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr, McConkey DJ, Keating MJ and Huang P: Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B-cells and overcome fludarabine resistance in CLL. Blood 107: 222-231, 2006.
4. Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL and McConkey DJ: Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65: 11510-11519, 2005. (Pubitemid 41821709)
5. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916, 2006.
6. Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5: 5-18, 2005.
7. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D and Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676-684, 2005. (Pubitemid 46237441)
8. Boelens J, Lust S, Offner F, Bracke ME and Vanhoecke BW: The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 21: 215-226, 2007. (Pubitemid 46534273)
9. Brostrom CO and Brostrom MA: Regulation of translational initiation during cellular responses to stress. Prog Nucleic Acid Res Mol Biol 58: 79-125, 1998.
10. Anether G, Tinhofer I, Senfter M and Greil R: Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2-independent pathway. Blood 101: 4561-4568, 2003. (Pubitemid 36857828)
11. Kelley TW, Alkan S, Srkalovic G and Hsi ED: Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 28: 845-850, 2004. (Pubitemid 38760046)
12. Gerhauser C: Beer constituents as potential cancer chemopreventive agents. Eur J Cancer 41: 1941-1954, 2005.
13. Vanhoecke B, Derycke L, Van Marck V, Depypere H, De Keukeleire D and Bracke M: Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer 117: 889-895, 2005. (Pubitemid 41688562)
14. Monteiro R, Calhau C, Silva AO, Pinheiro-Silva S, Guerreiro S, Gärtner F, Azevedo I and Soares R: Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J Cell Biochem 104(5): 1699-1707, 2008.
15. Colgate EC, Miranda CL, Stevens JF, Bray TM and Ho E: Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett 8: 201-209, 2007.
16. Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, Fassina G, Soverini S, Albini A and Ferrari N: Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol Cancer Ther 7(9): 2692-2702, 2008.
17. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the cysteine residues in IκBα kinase and NF-κB (p65) by xanthohumol leads to suppression of NF-κB-regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113(9): 2003-2013, 2009.
18. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M and Offner F: Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res 49: 844-850, 2005. (Pubitemid 41411568)
19. Dijsselbloem N, Goriely S, Albarani V, Gerlo S, Francoz S, Marine JC, Goldman M, Haegeman G and Vanden Berghe W: A critical role for p53 in the control of NF-kappaB-dependent gene expression in TLR4-stimulated dendritic cells exposed to genistein. J Immunol 178: 5048-5057, 2007. (Pubitemid 46595288)
20. Plaisance S, Vanden Berghe W, Boone E, Fiers W and Haegeman G: Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell Biol 17: 3733-3743, 1997. (Pubitemid 27281848)
21. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E and Haegeman G: Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 66: 4852-4862, 2006.
22. Pattyn F, Speleman F, De Paepe A and Vandesompele J: RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 31: 122-123, 2003. (Pubitemid 36150349)
23. Vandesompele J, De Paepe A and Speleman F: Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303: 95-98, 2002. (Pubitemid 34271110)
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7): research0034, 2002.
25. Ding L, Yan J, Zhu J, Zhong H, Lu Q, Wang Z, Huang C and Ye Q: Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res 31: 5266-5274, 2003. (Pubitemid 37441894)
26. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J and Elliott PJ: Proteasome inhibition measurements: Clinical applications. Clin Chem 46: 673-683, 2000. (Pubitemid 30318423)
27. Elliott PJ, Soucy TA, Pien CS, Adams J and Lightcap ES: Assays for proteasome inhibition. Methods Mol Med 85: 163-172, 2003.
28. Ito T, Warnken SP and May WS: Protein synthesis inhibition by flavonoids: roles of eukaryotic initiation factor 2alpha kinases. Biochem Biophys Res Commun 265: 589-594, 1999.
29. Wek RC, Jiang HY and Anthony TG: Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11, 2006.
30. Jiang HY, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR and Wek RC: Phosphorylation of the α subunit of eukaryotic initiation factor 2 is required for activation of NF-κB in response to diverse cellular stresses. Mol Cell Biol 23: 5651-5663, 2003. (Pubitemid 36951330)
31. Yoshida H, Oku M, Suzuki M and Mori K: pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. J Cell Biol 172: 565-575, 2006. (Pubitemid 43243877)
32. McCullough KD, Martindale JL, Klotz LO, Aw TY and Holbrook NJ: Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 21: 1249-1259, 2001.
33. Fribley A and Wang CY: Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 5: 745-748, 2006. (Pubitemid 44775127)
34. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL and McConkey DJ: Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65(24): 11658-11666, 2005. (Pubitemid 41821726)
35. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E and Sezer O: The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 17: 879-895, 2008. (Pubitemid 351864325)
36. Terpos E, Roussou M and Dimopoulos MA: Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol 4: 639-654, 2008.
37. Masdehors P, Merle-Béral H, Maloum K, Ömura S, Magdelénat H and Delic J: Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96: 269-274, 2000. (Pubitemid 30456481)
38. Bonfili L, Cecarini V, Amici M, Cuccioloni M, Angeletti M, Keller JN and Eleuteri AM: Natural polyphenols as proteasome modulators and their role as anti-cancer compounds. FEBS J 275: 5512-5526, 2008.
39. Magyar JE, Gamberucci A, Konta L, Margittai E, Mandl J, Bánhegyi G, Benedetti A and Csala M: Endoplasmic reticulum stress underlying the pro-apoptotic effect of epigallocatechin gallate in mouse hepatoma cells. Int J Biochem Cell Biol 41: 694-700, 2009.
40. Park JW, Woo KJ, Lee JT, Lim JH, Lee TJ, Kim SH, Choi YH and Kwon TK: Resveratrol induces pro-apoptotic endoplasmic reticulum stress in human colon cancer cells. Oncol Rep 18: 1269-1273, 2007.